FEG Investment Advisors hosted an Investment Symposium at Pegasus Park on May 3. The event welcomed more than 100 attendees to hear from industry leaders on investment, economic, and biotech trends.
During the Biotech Panel, Nolan Bean, Head of Institutional Investments at FEG led the discussion with Eli Casdin, CIO and Founder of Casdin Capital, and Kush Parmar, MD, Ph.D, Managing Partner at 5AM Ventures. While the market has been considerably rough to begin 2022, FEG believes in the long-term resiliency of the broader biotech market.
Fund Evaluation Group, LLC (FEG), a federally registered investment adviser under the Investment Advisers Act of 1940, as amended, providing non-discretionary and discretionary investment advice to its clients on an individual basis. Registration as an investment adviser does not imply a certain level of skill or training. The oral and written communications of an adviser provide you with information about which you determine to hire or retain an adviser. Fund Evaluation Group, LLC, Form ADV Part 2A & 2B can be obtained by written request directed to: Fund Evaluation Group, LLC, 201 East Fifth Street, Suite 1600, Cincinnati, OH 45202 Attention: Compliance Department.
The information in the articles is from various sources. Neither the information or any opinion expressed in any of the articles constitutes an offer, or an invitation to make an offer, to buy or sell any securities. FEG does not guarantee the accuracy or completeness of such information provided by third parties. The information is provided as of the date indicated and believed to be reliable. FEG assumes no obligation to update the information, or to advise on further developments relating to any article or the information referenced within.
Any awards or nominations received by FEG or its personnel are not representative of any client’s experience or FEG’s capabilities as an investment adviser and as such does not indicate any future experience or performance. FEG is not affiliated with the awarding agencies and does not validate the appropriateness of the agencies or its awards.